|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
nAMD and DME Management: Rapid Response From ARVO
Real-world outcomes with anti-vascular endothelial growth factor (VEGF) therapies in the management of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) are often not comparable to those of clinical studies. Discrepancies in these outcomes have been associated with undertreatment due to high treatment burden and the associated loss of patient adherence to dosing schedules. Newer therapies with novel mechanisms that extend intervals between dosing... |
|
Case Challenges in nAMD and DME Management: Achieving Durable Response
The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with uni... |
|
Meeting Milestones in nAMD and DME Management: What's New?
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionized treatment paradigms for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). However, these agents are associated with a high treatment burden because of the injection frequency, and a substantial number of patients do not adhere to their treatment schedules, resulting in suboptimal response to therapy. To address these issues, new dosage regimens and surgical drug delivery approaches hav... |
|
Ace the Case: A 65-Year-Old Woman With Chronic Diabetic Macular Edema in Both Eyes
In this clinical case review, Dr. Sara Haug explores considerations for the management of a patient with DME who is receiving monthly anti-VEGF therapy without attaining disease control. |